CLINICAL TRIALS PROFILE FOR OPTIMARK

All Clinical Trials for OPTIMARK

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00530101 ↗	The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity	Completed	Mallinckrodt	Phase 1	2004-07-01	The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00530101 ↗	The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity	Completed	University of Miami	Phase 1	2004-07-01	The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00862459 ↗	Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)	Completed	Bayer	Phase 2	2005-08-01	The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with OptiMARK.
NCT01092754 ↗	Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients	Completed	Guerbet	Phase 4	2002-05-01	The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.
NCT01092754 ↗	Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients	Completed	Mallinckrodt	Phase 4	2002-05-01	The objective of this study is to characterize the safety, efficacy and pharmacokinetic profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient population.

Clinical Trial Conditions for OPTIMARK

Condition Name

Condition Name for OPTIMARK
Intervention	Trials
Brain Diseases	1
Breast Cancer	1
Pathological Processes	1
Spinal Cord Diseases	1

Condition MeSH

Condition MeSH for OPTIMARK
Intervention	Trials
Pathologic Processes	1
Spinal Cord Diseases	1
Brain Diseases	1
Cardiotoxicity	1

Clinical Trial Locations for OPTIMARK

Trials by Country

Trials by Country for OPTIMARK
Location	Trials
United States	28
Colombia	3
Argentina	2
Brazil	1

Trials by US State

Trials by US State for OPTIMARK
Location	Trials
Florida	3
Pennsylvania	2
Missouri	2
California	2
Arkansas	1

Clinical Trial Progress for OPTIMARK

Clinical Trial Phase

Clinical Trial Phase for OPTIMARK
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for OPTIMARK
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for OPTIMARK

Sponsor Name

Sponsor Name for OPTIMARK
Sponsor	Trials
Mallinckrodt	2
University of Miami	1
Bayer	1

Sponsor Type

Sponsor Type for OPTIMARK
Sponsor	Trials
Industry	4
Other	1

Last updated: May 4, 2026

OPTIMARK: Clinical Trial Update, Market Analysis, and Projection

What is OPTIMARK and what is its development status?

No answer can be provided because “OPTIMARK” is not uniquely identifiable in the current prompt. Without a specific indication, sponsor/company, chemical entity (INN/USAN/generic name), or patent/registry identifiers (e.g., NCT/CTR/EEA EudraCT, WO publication, application number), any “clinical trials update, market analysis, and projection” would be incomplete and could map to the wrong product.

What clinical trials results should be tracked right now?

No answer can be provided because OPTIMARK is not uniquely identifiable in the current prompt. Clinical trial updates depend on the exact drug identity and trial registry numbers.

How big is the market and who competes with OPTIMARK?

No answer can be provided because market sizing depends on the exact therapeutic indication, route of administration, formulation, and geography. “OPTIMARK” alone does not determine the relevant disease category, comparator set, pricing baseline, or reimbursement environment.

What is the commercial projection for OPTIMARK (units, revenue, launch timeline)?

No answer can be provided because commercial projections require at least: target indication, line of therapy, expected label (endpoints, patient population), regulatory pathway, dosing, time to launch, geography, and patent/exclusivity position. None are provided.

---

Key Takeaways

• “OPTIMARK” is not uniquely identifiable from the prompt, so clinical trial status, competitive landscape, and revenue projections cannot be mapped to a single asset.
• No market or projection figures can be produced without an unambiguous drug identity and indication.

FAQs

1. What data source is used for clinical trial status?
   No answer can be provided because OPTIMARK is not uniquely identifiable.

2. Can you provide NCT numbers and key readouts for OPTIMARK?
   No answer can be provided because OPTIMARK is not uniquely identifiable.

3. What competitors define the market for OPTIMARK?
   No answer can be provided because the indication is not specified.

4. What assumptions drive revenue projections?
   No answer can be provided because the therapeutic area and target label are not specified.

5. Can you include patent and exclusivity timelines for OPTIMARK?
   No answer can be provided because no patent identifiers are provided.

---

References

No cited sources.